{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:34:57Z","timestamp":1787495697959,"version":"build-2736575974"},"reference-count":35,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Vertex Pharmaceuticals Incorporated","award":["No award\/grant number"],"award-info":[{"award-number":["No award\/grant number"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2024,4,21]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ivacaftor (IVA) has been shown to improve lung function and other clinical outcomes in people with cystic fibrosis (CF). A decade of real-world IVA availability has enabled the examination of long-term outcomes with this treatment. This retrospective, longitudinal cohort study investigated the impact of IVA on mortality rate and health outcomes among people with CF in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from the US CF Foundation Patient Registry from January 2010 to December 2019 were analysed. The IVA-treated cohort included people with a CF transmembrane conductance regulator (\n                      <jats:italic>CFTR<\/jats:italic>\n                      ) gating mutation (excluding\n                      <jats:italic>R117H<\/jats:italic>\n                      ); age-matched comparator cohort included people with a\n                      <jats:italic>F508del<\/jats:italic>\n                      and a minimal function\n                      <jats:italic>CFTR<\/jats:italic>\n                      mutation who had no prior CFTR modulator treatment. Baseline characteristics were balanced between cohorts using standardised mortality ratio weighting generated from propensity scores. Outcomes of interest were overall survival, lung transplant, percent predicted forced expiratory volume in 1\u2009s (ppFEV\n                      <jats:sub>1<\/jats:sub>\n                      ), body mass index (BMI), pulmonary exacerbations (PEx), outpatient visits and hospitalisations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      Over a maximum follow-up of 7.9 years, the IVA-treated cohort (N=736) had lower rates of mortality (hazard ratio [HR] (95%\u2009CI): 0.22 (0.09 to 0.45)), lung transplant (HR: 0.11 (95% CI 0.02 to 0.28)), PEx (rate ratio: 0.49 (95% CI 0.42 to 0.55)) and all-cause hospitalisations (rate ratio: 0.50 (95% CI 0.43 to 0.56)) as well as better lung function (mean difference in ppFEV\n                      <jats:sub>1<\/jats:sub>\n                      : 8.46 (95% CI 7.34 to 9.75)) and higher BMI\/BMI\n                      <jats:italic>z<\/jats:italic>\n                      -scores (mean difference 1.20 (95% CI 0.92 to 1.71)\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and 0.27 (95% CI 0.25 to 0.40), respectively) than the comparator cohort (N=733).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Our analysis suggests that IVA provides sustained clinical benefits in people with CF over a follow-up period of approximately 8 years. These findings reinforce the existing real-world evidence that IVA can slow disease progression and decrease the healthcare burden of CF over the long term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2023-220558","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T15:36:40Z","timestamp":1719502600000},"page":"925-933","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-3928","authenticated-orcid":false,"given":"Christian A","family":"Merlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teja","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqian M","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime L","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Alan","family":"Brookhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"2025012402150928000_79.10.925.1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025012402150928000_79.10.925.2","unstructured":"Patient Registry 2021 Annual Data Report . Cystic Fibrosis Foundation. Bethesda, MD, 2022."},{"key":"2025012402150928000_79.10.925.3","unstructured":"European Cystic Fibrosis Society . Patient Registry 2020 Annual Data Report, 2022. Available: https:\/\/www.ecfs.eu\/projects\/ecfs-patient-registry\/annual-reports [Accessed 6 Dec 2022]."},{"key":"2025012402150928000_79.10.925.4","unstructured":"Cystic Fibrosis Canada . The Canadian Cystic Fibrosis Registry 2021 Annual Data Report, Available: https:\/\/www.cysticfibrosis.ca\/registry\/2021AnnualDataReport.pdf [Accessed 15 Nov 2023]."},{"key":"2025012402150928000_79.10.925.5","unstructured":"Cystic Fibrosis Australia . Australian Cystic Fibrosis Data Registry Annual Report, 2021. Available: https:\/\/cysticfibrosis.org.au\/wp-content\/uploads\/2023\/05\/2021-ACFDR-Annual-Report.pdf [Accessed 15 Nov 2023]."},{"key":"2025012402150928000_79.10.925.6","unstructured":"Cystic Fibrosis Foundation . Patient Registry 2011 Annual Data Report. Bethesda, MD, 2012."},{"key":"2025012402150928000_79.10.925.7","unstructured":"Kalydeco (Ivacaftor) Prescribing Information . Boston, MA: Vertex Pharmaceuticals Incorporated, 2012."},{"key":"2025012402150928000_79.10.925.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.12.005"},{"key":"2025012402150928000_79.10.925.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2025012402150928000_79.10.925.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201301-0153OC"},{"key":"2025012402150928000_79.10.925.11","unstructured":"Kalydeco (Ivacaftor) Prescribing Information . Boston, MA: Vertex Pharmaceuticals Incorporated,"},{"key":"2025012402150928000_79.10.925.12","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of Ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"The Lancet Respiratory Medicine"},{"key":"2025012402150928000_79.10.925.13","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210394"},{"key":"2025012402150928000_79.10.925.14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with Ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025012402150928000_79.10.925.15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071527","article-title":"Real-world outcomes of Ivacaftor treatment in people with cystic fibrosis: a systematic review","volume":"10","author":"Duckers","year":"2021","journal-title":"J Clin Med"},{"key":"2025012402150928000_79.10.925.16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","article-title":"Real-world outcomes among patients with cystic fibrosis treated with Ivacaftor: 2012\u20132016 experience","volume":"6","author":"Higgins","year":"2020","journal-title":"Pulm Ther"},{"key":"2025012402150928000_79.10.925.17","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201511-781OC"},{"key":"2025012402150928000_79.10.925.18","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.092056"},{"key":"2025012402150928000_79.10.925.19","doi-asserted-by":"crossref","unstructured":"Bresnick K , Arteaga-Solis E , Millar SJ , et al . Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies. BMJ Open Respir Res 2021;8. doi:10.1136\/bmjresp-2021-000998","DOI":"10.1136\/bmjresp-2021-000998"},{"key":"2025012402150928000_79.10.925.20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jcf.2021.07.003","article-title":"Disease burden in people with cystic fibrosis heterozygous for F508Del and a minimal function Mutation","volume":"21","author":"Sawicki","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025012402150928000_79.10.925.21","doi-asserted-by":"crossref","unstructured":"Lopes-Pacheco M . CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 2020;10. doi:10.3389\/fphar.2019.01662","DOI":"10.3389\/fphar.2019.01662"},{"key":"2025012402150928000_79.10.925.22","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12197"},{"key":"2025012402150928000_79.10.925.23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1358\/dot.2013.49.4.1940984","article-title":"Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis","volume":"49","author":"McPhail","year":"2013","journal-title":"Drugs Today (Barc)"},{"key":"2025012402150928000_79.10.925.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2016.03.002"},{"key":"2025012402150928000_79.10.925.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.03.006"},{"key":"2025012402150928000_79.10.925.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1421OC"},{"key":"2025012402150928000_79.10.925.27","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21374"},{"key":"2025012402150928000_79.10.925.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159111"},{"key":"2025012402150928000_79.10.925.29","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2011.161117"},{"key":"2025012402150928000_79.10.925.30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025012402150928000_79.10.925.31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1377\/hlthaff.2017.1554","article-title":"Precision medicine in action: the impact of Ivacaftor on cystic fibrosis\u2013related hospitalizations","volume":"37","author":"Feng","year":"2018","journal-title":"Health Affairs"},{"key":"2025012402150928000_79.10.925.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201404-0703OC"},{"key":"2025012402150928000_79.10.925.33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s41030-021-00154-9","article-title":"Long-term impact of Ivacaftor on healthcare resource utilization among people with cystic fibrosis in the United States","volume":"7","author":"Thorat","year":"2021","journal-title":"Pulm Ther"},{"key":"2025012402150928000_79.10.925.34","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1164\/rccm.201608-1678LE","article-title":"Patients with cystic fibrosis and a G551D or homozygous F508Del Mutation: similar lung function decline","volume":"195","author":"Sawicki","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025012402150928000_79.10.925.35","unstructured":"Food US , Administration D . FDA approves new breakthrough therapy for cystic fibrosis, Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-breakthrough-therapy-cystic-fibrosis [Accessed 21 Mar 2023]."}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-220558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:17:42Z","timestamp":1737695862000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-220558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,9,18]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/thorax-2023-220558"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-220558","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}